Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection
Xiaoxiao Qi, Bixia Ke, Feng Qian, Deying Yang, Qinghai Lian, Zibo Li, Linlin Lu, Changwen Ke, Zhongqiu Liu, Guochao Liao
Abstract
Herein, we report that a recombinant fusion protein, containing a 457 amino acid SARS-CoV-2 receptor binding domain (RBD, residues 319-541) and a mouse IgG1 Fc domain, could induce highly potent neutralizing antibodies and stimulate humoral and cellular immunity in mice. The antibodies also effectively suppressed SARS-CoV-2 RBD binding to soluble ACE2, indicating that RBD-mFc may be further developed as a safe and effective SARS-CoV-2 vaccine.
Topics & Concepts
Recombinant DNAProtein subunitAntibodyFusion proteinSpike ProteinVirologyReceptorBinding domainHumoral immunityChemistryDomain (mathematical analysis)BiologyImmunityMolecular biologyImmune systemBinding siteCoronavirus disease 2019 (COVID-19)BiochemistryImmunologyMedicineGeneMathematical analysisPathologyInfectious disease (medical specialty)DiseaseMathematicsSARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies ResearchInfluenza Virus Research Studies